News | November 28, 2024
Senores Pharmaceuticals launches Ivermectin Tablets in US with Dr. Reddy's Laboratories
The product will be marketed by Dr. Reddy's
The product will be marketed by Dr. Reddy's
This transaction is the third acquisition by three different Japanese players in this segment
Utidelone can penetrate BBB due to its unique physicochemical characteristics and insusceptibility to P-glycoprotein-mediated efflux
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024 has expanded to 42 patients with clinical complete response
Merck shared updates on the company’s oncology pipeline and focused R&D approach
Third Phase 3 trial in third type of lymphoma to show improvement in overall survival with an ADCETRIS-containing regimen
The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas
Acceptance based on results demonstrated a statistically significant improvement in overall survival versus chemotherapy alone in these patients
These abstracts report on the company's three lead drug candidates, including olverembatinib
Subscribe To Our Newsletter & Stay Updated
